3 completed, 1 unknown, 1 withdrawn. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow Sofosbuvir 400 mg: new trials by email Literature Review of Sofosbuvir 400 mg trials Research Report on Sofosbuvir 400 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hepatitis C Treatment Study in Myanmar Sofosbuvir 400 mg - Hepatitis C | Withdrawn | Myanmar Oxford Clinical Research Unit | 2022-01-01 | 2021-12-17 | ||
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C | Phase 2 | Completed | University of Dundee | 129 | 2018-01-19 | 2021-11-18 |
| Hepatitis c and Vitamin D and Iron Status Sofosbuvir 400 mg, Daclatasvir 60 mg/day - Hepatitis C | Unknown | Eman Sayed Hassan Abd Allah | 87 | 2017-06-01 | 2017-05-25 | |
| Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg - Hepatitis C Virus | Phase 2 | Completed | Janssen Research & Development, LLC | 68 | 2015-01-01 | 2017-03-01 |
Hepatitis C (5) · Fibrosis (1) · Liver Cirrhosis (1) · Substance-Related Disorders (1)
Eman Sayed Hassan Abd Allah (1) · Janssen Research & Development, LLC (1) · Muhammad Radzi Abu Hassan (1) · Myanmar Oxford Clinical Research Unit (1) · University of Dundee (1)
Burma (1) · Canada (1) · Malaysia (1) · United Kingdom (1) · United States (1)
Eman SH Abd Allah, PHD (1) · John Dillon, MD (1) · Khin Pyone Kyi, MB BS (1) · Muhammad Radzi Abu Hassan, FRCP (1) · Ni Ni Tun, MB BS (1)
PMID 29274193, PMID 31399460, PMID 35582875, PMID 42140479, PMID 42277657
2017 (1)